Large bone defects face a high risk of pathogen exposure due to open wounds,which leads to high infection rates and delayed bone union.To promote successful repair of infectious bone defects,fabrication of a scaffold ...Large bone defects face a high risk of pathogen exposure due to open wounds,which leads to high infection rates and delayed bone union.To promote successful repair of infectious bone defects,fabrication of a scaffold with dual functions of osteo-induction and bacterial inhibition is required.This study describes creation of an engineered progenitor cell line(C3H10T1/2)capable of doxycycline(DOX)-mediated release of bone morphogenetic protein-2(BMP2).Three-dimensional bioprinting technology enabled creation of scaffolds,comprising polycaprolactone/mesoporous bioactive glass/DOX and bioink,containing these engineered cells.In vivo and in vitro experiments confirmed that the scaffold could actively secrete BMP2 to significantly promote osteoblast differentiation and induce ectopic bone formation.Additionally,the scaffold exhibited broad-spectrum antibacterial capacity,thereby ensuring the survival of embedded engineered cells when facing high risk of infection.These findings demonstrated the efficacy of this bioprinted scaffold to release BMP2 in a controlled manner and prevent the occurrence of infection;thus,showing its potential for repairing infectious bone defects.展开更多
Background:Postoperative pulmonary complications often lead to increased mortality and financial burden.Residual paralysis plays a critical role in postoperative pulmonary complications.This meta-analysis was performe...Background:Postoperative pulmonary complications often lead to increased mortality and financial burden.Residual paralysis plays a critical role in postoperative pulmonary complications.This meta-analysis was performed to determine whether sugammadex overmatches neostigmine in reducing postoperative pulmonary complications.Methods:PubMed,Embase,Web of Science,Medline through Ovid,Cochrane Library,Wanfang,China National Knowledge Infrastructure,and Chinese BioMedical Literature Databases were searched from their inception to 24 June,2021.Random effects models were used for all analyses.Cochrane risk of bias tool was used to assess the quality of RCTs,while Newcastle Ottawa Quality Assessment Scale was used to assess for the quality of cohort studies.Results:Seventeen studies were included in the meta-analysis.Pooled data from cohort studies showed reversing neuromuscular blocking with sugammadex had less risk of compound postoperative pulmonary complications(relative risk[RR]:0.73;95%confidence interval[CI]:0.60-0.89;P=0.002;I^(2)=81%),pneumonia(RR:0.64;95%CI:0.48-0.86;I^(2)=42%)and respiratory failure(RR:0.48;95%CI:0.41-0.56;I^(2)=0%).However,pooled data from RCTs did not show any difference between the two groups in pneumonia(RR:0.58;95%CI:0.24-1.40;I^(2)=0%)and no respiratory failure was reported in the included RCTs.The difference was not found between sugammadex and neostigmine about atelectasis in pooled data from either RCTs(RR:0.85;95%CI:0.69-1.05;I^(2)=0%)or cohort studies(RR:1.01;95%CI:0.87-1.18;I^(2)=0%).Conclusion:The evidence of superiority of sugammadex was limited by the confounding factors in cohort studies and small scale of RCTs.Whether sugammadex precedes neostigmine in preventing pulmonary complications after surgery is still unknown.Well-designed RCTs with large scale are needed.Registration:PROSPERO(https://www.crd.york.ac.uk/PROSPERO/);CRD 42020191575.展开更多
基金supported by the National Key R&D Program(grant no.2016YFC1102100)a NSFC grant(grant no.81921002)the Shanghai Science and Technology Development Fund(grant no.18DZ2291200 and 18441902700).
文摘Large bone defects face a high risk of pathogen exposure due to open wounds,which leads to high infection rates and delayed bone union.To promote successful repair of infectious bone defects,fabrication of a scaffold with dual functions of osteo-induction and bacterial inhibition is required.This study describes creation of an engineered progenitor cell line(C3H10T1/2)capable of doxycycline(DOX)-mediated release of bone morphogenetic protein-2(BMP2).Three-dimensional bioprinting technology enabled creation of scaffolds,comprising polycaprolactone/mesoporous bioactive glass/DOX and bioink,containing these engineered cells.In vivo and in vitro experiments confirmed that the scaffold could actively secrete BMP2 to significantly promote osteoblast differentiation and induce ectopic bone formation.Additionally,the scaffold exhibited broad-spectrum antibacterial capacity,thereby ensuring the survival of embedded engineered cells when facing high risk of infection.These findings demonstrated the efficacy of this bioprinted scaffold to release BMP2 in a controlled manner and prevent the occurrence of infection;thus,showing its potential for repairing infectious bone defects.
基金Sichuan Science and Technology Program(Nos.2020YFS0188 and 2020YJ0283)
文摘Background:Postoperative pulmonary complications often lead to increased mortality and financial burden.Residual paralysis plays a critical role in postoperative pulmonary complications.This meta-analysis was performed to determine whether sugammadex overmatches neostigmine in reducing postoperative pulmonary complications.Methods:PubMed,Embase,Web of Science,Medline through Ovid,Cochrane Library,Wanfang,China National Knowledge Infrastructure,and Chinese BioMedical Literature Databases were searched from their inception to 24 June,2021.Random effects models were used for all analyses.Cochrane risk of bias tool was used to assess the quality of RCTs,while Newcastle Ottawa Quality Assessment Scale was used to assess for the quality of cohort studies.Results:Seventeen studies were included in the meta-analysis.Pooled data from cohort studies showed reversing neuromuscular blocking with sugammadex had less risk of compound postoperative pulmonary complications(relative risk[RR]:0.73;95%confidence interval[CI]:0.60-0.89;P=0.002;I^(2)=81%),pneumonia(RR:0.64;95%CI:0.48-0.86;I^(2)=42%)and respiratory failure(RR:0.48;95%CI:0.41-0.56;I^(2)=0%).However,pooled data from RCTs did not show any difference between the two groups in pneumonia(RR:0.58;95%CI:0.24-1.40;I^(2)=0%)and no respiratory failure was reported in the included RCTs.The difference was not found between sugammadex and neostigmine about atelectasis in pooled data from either RCTs(RR:0.85;95%CI:0.69-1.05;I^(2)=0%)or cohort studies(RR:1.01;95%CI:0.87-1.18;I^(2)=0%).Conclusion:The evidence of superiority of sugammadex was limited by the confounding factors in cohort studies and small scale of RCTs.Whether sugammadex precedes neostigmine in preventing pulmonary complications after surgery is still unknown.Well-designed RCTs with large scale are needed.Registration:PROSPERO(https://www.crd.york.ac.uk/PROSPERO/);CRD 42020191575.
